Aussie Biotechs Look To Federal Budget For Research Support
This article was originally published in PharmAsia News
Executive SummaryAustralian biotechs are looking for help in the federal budget for supporting life sciences in the wake of a 24 percent decline in research spending among startups in the first quarter. The decline is the biggest in the three years since the industry began analyzing research spending. Spending amounted to just under $30 million in the first quarter, compared with $39 million in the previous quarter. Australia's Commercial Ready grants program was cut in last year's budget, so the life sciences sector is awaiting the new budget and details for replacement programs. (Click here for more
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.